CPC G01N 33/57496 (2013.01) [A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5017 (2013.01); G01N 33/57484 (2013.01); G01N 33/57492 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/70517 (2013.01)] | 21 Claims |
1. A method for the treatment of solid tumor cancer in a subject that has one or more tumors that exclude T-cell infiltration, the method comprising (a) testing tumor cells or tissue from a subject for one or more of: (i) exclusion of T cell infiltration, (ii) transcriptional repression of chemokine CCL4, (iii) defective recruitment of CD103+dendritic cells; and (b) co-administrating (i) a β-catenin inhibitor and/or a Wnt/β-catenin pathway inhibitor and (ii) dendritic-cell therapy or T-cell therapy to the subject.
|